133 related articles for article (PubMed ID: 15708246)
1. Hormone therapy and radiotherapy for early prostate cancer: a utility-adjusted number needed to treat (NNT) analysis.
Jani AB; Kao J; Heimann R; Hellman S
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):687-94. PubMed ID: 15708246
[TBL] [Abstract][Full Text] [Related]
2. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
Jani AB; Kao J; Hellman S
Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
[TBL] [Abstract][Full Text] [Related]
3. Androgen ablation adjuvant to postprostatectomy radiotherapy: complication-adjusted number needed to treat analysis.
Jani AB; Sokoloff M; Shalhav A; Stadler W
Urology; 2004 Nov; 64(5):976-81. PubMed ID: 15533489
[TBL] [Abstract][Full Text] [Related]
4. Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique.
Jani AB
Cancer Invest; 2006; 24(3):318-27. PubMed ID: 16809161
[TBL] [Abstract][Full Text] [Related]
5. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
6. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
[TBL] [Abstract][Full Text] [Related]
7. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
[TBL] [Abstract][Full Text] [Related]
8. [Prostate cancer at high risk of recurrence: results of 12 months of radiotherapy-hormone therapy].
Delaporte V; Muracciole X; Lechevallier E; Bastide C; Cowen D; Rossi D; Coulange C
Prog Urol; 2005 Apr; 15(2):260-4. PubMed ID: 15999604
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit for early hormone ablation in biochemically recurrent prostate cancer.
Tenenholz TC; Shields C; Ramesh VR; Tercilla O; Hagan MP
Urol Oncol; 2007; 25(2):101-9. PubMed ID: 17349523
[TBL] [Abstract][Full Text] [Related]
10. Postprostatectomy adjuvant versus salvage radiotherapy: a complication-adjusted number-needed-to-treat analysis.
Jani AB; Kao J
Cancer; 2005 May; 103(9):1833-42. PubMed ID: 15756656
[TBL] [Abstract][Full Text] [Related]
11. Survival benefit associated with adjuvant androgen deprivation therapy combined with radiotherapy for high- and low-risk patients with nonmetastatic prostate cancer.
Zeliadt SB; Potosky AL; Penson DF; Etzioni R
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):395-402. PubMed ID: 16904843
[TBL] [Abstract][Full Text] [Related]
12. Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02.
Rosenthal SA; Bae K; Pienta KJ; Sobczak ML; Asbell SO; Rajan R; Kerlin KJ; Michalski JM; Sandler HM;
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):672-8. PubMed ID: 18990504
[TBL] [Abstract][Full Text] [Related]
13. Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mL.
Berthelet E; Pickles T; Lee KW; Liu M; Truong PT;
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):781-7. PubMed ID: 16199312
[TBL] [Abstract][Full Text] [Related]
14. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
15. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
Moreau JP; Delavault P; Blumberg J
Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
[TBL] [Abstract][Full Text] [Related]
16. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features.
Vargas C; Martínez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J
Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040
[TBL] [Abstract][Full Text] [Related]
17. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Beyer DC; McKeough T; Thomas T
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of hormonal manipulation as monotherapy or adjuvant treatment in localised prostate cancer.
Abrahamsson PA; Anderson J; Boccon-Gibod L; Schulman C; Studer UE; Wirth M
Eur Urol; 2005 Dec; 48(6):900-5. PubMed ID: 16257109
[TBL] [Abstract][Full Text] [Related]
19. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
[TBL] [Abstract][Full Text] [Related]
20. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]